Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Raymond D, Pratt"'
Publikováno v:
Archives of Clinical Nephrology. :044-049
Retrospective observational analysis of ferric pyrophosphate citrate (triferic®) administered via dialysate. Experience at a single facility over 2 years
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3e54f07b6ac056dd106ce097169a24f
https://doi.org/10.17352/acn.000055
https://doi.org/10.17352/acn.000055
Publikováno v:
Current medical research and opinion. 38(8)
Anemia is a common complication in patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). Anemia is principally the result of erythropoietin deficiency, inflammation, and iron deficiency. High molecular weight iron oxide nanoparticles
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::651d00c1e36e6b26d4912e35be57ecb2
https://pubmed.ncbi.nlm.nih.gov/35726771
https://pubmed.ncbi.nlm.nih.gov/35726771
Publikováno v:
Journal of Clinical Pharmacology
Ferric pyrophosphate citrate (Triferic) is a water‐soluble iron salt that is administered via dialysate to maintain iron balance and hemoglobin in hemodialysis patients. This double‐blind, randomized, placebo‐controlled, single‐, ascending‐
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::59cce6f9661b81a0258f73f07ee04c8d
https://pubmed.ncbi.nlm.nih.gov/27557937
https://pubmed.ncbi.nlm.nih.gov/27557937
Publikováno v:
Current Medical Research and Opinion. 25:3021-3028
Epidemiological data link elevated levels of serum phosphorus with increased mortality among patients with chronic kidney disease. Recent data also suggest improved survival with the use of dietary phosphate binders in patients on dialysis. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3accf2e72232971fdb13f4c4d1b3c99
https://doi.org/10.1185/03007990903399398
https://doi.org/10.1185/03007990903399398
Publikováno v:
Kidney International. 74(2):148-157
Observational studies have determined hyperphosphatemia to be a cardiovascular risk factor in chronic kidney disease. Mechanistic studies have elucidated that hyperphosphatemia is a direct stimulus to vascular calcification, which is one cause of mor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0126173fb4503f4b50cc73fa554b361b
Autor:
Robert L. Findling, Frank A. Lopez, Raun D. Melmed, Floyd R. Sallee, L. Eugene Arnold, Raymond D. Pratt, Oscar G. Bukstein
Publikováno v:
The Journal of Clinical Psychiatry. 69:149-159
OBJECTIVE To evaluate the efficacy and safety of methylphenidate transdermal system compared with placebo, using osmotic-release oral system (OROS) methylphenidate as a reference therapy. METHOD We conducted a 7-week, randomized, double-blind, double
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d51db8d5724ae27571bec6f96f1618b
https://doi.org/10.4088/jcp.v69n0120
https://doi.org/10.4088/jcp.v69n0120
Autor:
Daniel F. Connor, Samuel W. Boellner, Howard Abikoff, Thomas J. Spencer, Raymond D. Pratt, Stephanie C Read, Joseph Biederman, Steven R. Pliszka
Publikováno v:
Clinical Therapeutics. 28:402-418
Oppositional defiant disorder (ODD)is associated with a high degree of impairment in social skills, family interaction, and academic functioning. Comorbid ODD is reportedly present in 40% to 70% of children and adolescents with attention-deficit/hype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15fdf7864b2fb1b083503ce5238e6154
https://doi.org/10.1016/j.clinthera.2006.03.006
https://doi.org/10.1016/j.clinthera.2006.03.006
Autor:
Raymond D. Pratt, Joseph Biederman, Richard H. Weisler, Timothy E. Wilens, Thomas J. Spencer, Stephanie C. Read
Publikováno v:
Clinical Therapeutics. 28:266-279
The ability to recognize and diagnose attention-deficit/hyperactivity disorder (ADHD) has increased in recent years. The persistence of ADHD symptoms puts adolescents with ADHD at risk for long-term adverse psychosocial outcomes.The primary goal of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79d1e65e86d0facbe44221f27ba3b214
https://doi.org/10.1016/j.clinthera.2006.02.011
https://doi.org/10.1016/j.clinthera.2006.02.011
Autor:
Ramon Vargas, Raymond D. Pratt, Carlos Perdomo, Josephine F. Reyes, Dinesh Kumar, Edward I. Cullen
Publikováno v:
British Journal of Clinical Pharmacology. 58:9-17
Aims To evaluate the pharmacokinetics (PK), pharmacodynamics (PD), tolerability and safety of donepezil HCl 5 mg following oral doses for 1 and 24 days in hepatically impaired patients compared with healthy controls under steady-state, multiple-dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b940afcf0478684494cdc8dd78ddcc42
https://doi.org/10.1111/j.1365-2125.2004.01802.x
https://doi.org/10.1111/j.1365-2125.2004.01802.x
Autor:
H. Wayne Hutman, Thomas Marbury, W. Kline Bolton, Dinesh Kumar, Christa F. Nagy, Maria Gutierrez, Raymond D. Pratt, Edward I. Cullen
Publikováno v:
British Journal of Clinical Pharmacology. 58:18-24
To characterize the pharmacokinetic, pharmacodynamic and safety profiles of donepezil in subjects with moderate renal impairment and matched healthy controls during single-dose and multiple-dose phases.This open-label study enrolled subjects with mod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40477e476f98c7f23677c2f1e6a029f1
https://doi.org/10.1111/j.1365-2125.2004.01803.x
https://doi.org/10.1111/j.1365-2125.2004.01803.x